Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $821.96M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.30M
Average 1.70M
Returns on capital
Syndax Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-441.6%
avg -100.8%
ROIC
-66.6%
avg -51.8%
ROA
-53.9%
avg -42.6%
Analysis
ROA is currently the strongest return metric at -53.9% versus its period average of -42.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Michael A. Metzger | Chief Executive Officer & Director | USD 1.61M | 55 | 0 | <0.01% |
Nicholas Botwood MBBS | Head of Research & Development and Chief Medical Officer | USD 876.85K | 58 | — | — |
Keith Alan Goldan | CFO, Treasurer & Principal Accounting Officer | USD 852.55K | 55 | — | — |
Luke J. Albrecht | General Counsel & Corporate Secretary | USD 842.31K | 47 | — | — |
Steven Closter | Chief Commercial Officer | USD 822.88K | 57 | — | — |
Peter Ordentlich | Co-Founder & Chief Scientific Officer | — | 57 | 0 | <0.01% |
Ronald Evans | Co-Founder, Advisor and Chair of Scientific Advisory Board | — | 76 | — | — |
Averi Price | Senior VP of Legal & Chief Compliance Officer | — | — | — | — |
Sharon Klahre | Vice President of Investor Relations & Communications | — | — | — | — |
Michael Downes | Co-Founder | — | — | — | — |
Richard A. Heyman | Co-Founder | — | 69 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 8, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$2.86M
Net Transaction Value
−$2.86M
Net selling
Most Active
Metzger Michael A
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 29, 26Oct 29, 2026 | Podlesak Dennis Direct | Sell | $113.7K$113,716.00 |
| Jul 8, 26Jul 8, 2026 | Metzger Michael A Direct | Sell | $784.8K$784,776.48 |
| Jun 12, 26Jun 12, 2026 | Botwood Nicholas A.J. Direct | Sell | $566.6K$566,602.90 |
| Jun 11, 26Jun 11, 2026 | Botwood Nicholas A.J. Direct | Sell | $617K$617,040.00 |
| Jun 1, 26Jun 1, 2026 | Goldan Keith A. Direct | Sell | $22.4K$22,351.23 |
| Jun 1, 26Jun 1, 2026 | Metzger Michael A Direct | Sell | $130K$130,024.53 |
| Feb 9, 26Feb 9, 2026 | Metzger Michael A Direct | Sell | $360.8K$360,819.45 |
| Feb 9, 26Feb 9, 2026 | Goldan Keith A. Direct | Sell | $71.7K$71,705.48 |
| Feb 6, 26Feb 6, 2026 | Metzger Michael A Direct | Sell | $152.8K$152,835.44 |
| Feb 6, 26Feb 6, 2026 | Goldan Keith A. Direct | Sell | $42.9K$42,930.84 |
Summary
Insiders reported 0 buys worth $0.00 and 10 sells worth $2.86M over the last 12 months. That adds up to net selling of $2.86M. Metzger Michael A was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +44.1% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +44.1% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Syndax Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about SNDX's management, answered from reported figures.
Who manages SNDX?
Syndax Pharmaceuticals, Inc. (SNDX) lists 11 active executives. The top listed executive is Peter Ordentlich, Co-Founder & Chief Scientific Officer.
Are SNDX insiders buying or selling?
Recent insider activity shows net buying of $50.76M.
Continue the stock analysis
Jump to another research area for this company.